關(guān)鍵詞： Celgene 銷(xiāo)售額翻番
2013年1月9日訊 /生物谷BIOON/ --Celgene公司CEO Bob Hugin日前在JP摩根健康產(chǎn)業(yè)投資大會(huì)上宣布了該公司未來(lái)五年的發(fā)展計(jì)劃,，計(jì)劃中預(yù)測(cè)Celgene公司將用5年的時(shí)間使公司的銷(xiāo)售額翻倍。與此同時(shí),，他還著重強(qiáng)調(diào)了Celgene公司研發(fā)的治療牛皮癬的藥物apremilast三期研究的情況,，并稱這項(xiàng)研究工作對(duì)公司五年計(jì)劃有著很大的促進(jìn)作用,。
目前公司正在進(jìn)行的幾項(xiàng)重要研究如治療多發(fā)性骨髓瘤藥物pomalidomide的研究,，治療胰腺癌藥物Abraxanede的研究都有助于公司目標(biāo)的實(shí)現(xiàn),。（生物谷Bioon.com）
詳細(xì)英文報(bào)道：
Celgene ($CELG) captured the center ring at the J.P. Morgan conference on its opening day Monday. Company CEO Bob Hugin boldly mapped out a 5-year plan to double sales and highlighted upbeat Phase III data on its psoriasis drug apremilast that he believes will set the stage for regulatory approval on both sides of the Atlantic.
Touting plans to grow sales of its blockbuster Revlimid, Hugin says that the company is advancing three new blockbuster programs that will help drive revenue to $12 billion a year by 2017. Hugin is looking for an FDA approval of its multiple myeloma drug pomalidomide (to be sold as Pomalyst) soon, with a filing for apremilast slated for the second half of this year. And Celgene expects to file Abraxane for pancreatic cancer later this year as well.
"The accomplishments of 2012 and our outlook for 2013 have positioned us with significant catalysts as we enter a new growth phase for Celgene in all three therapeutic areas of our business--hematology, oncology and inflammation and immunology," said Hugin in a statement. "The increased visibility we now have to many of those catalysts allows us to reaffirm our 2015 targets and give new targets out to 2017."
That assessment drew some rave reviews from analysts, who helped cheer on a rally for Celgene's stock.
"We believe Celgene is re-emerging as a clean, earnings-driven growth stock as Abraxane's potential in pancreatic cancer becomes more fully appreciated and Revlimid gets back on track with European regulators," Cowen's Eric Schmidt told MarketWatch. "We expect Celgene's stock multiple to expand as a result."
